tradingkey.logo

Trinity Biotech PLC

TRIB
View Detailed Chart
1.000USD
+0.019+1.96%
Close 11/04, 16:00ETQuotes delayed by 15 min
8.29MMarket Cap
LossP/E TTM

Trinity Biotech PLC

1.000
+0.019+1.96%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.96%

5 Days

0.00%

1 Month

-13.04%

6 Months

+17.65%

Year to Date

+13.61%

1 Year

-40.83%

View Detailed Chart

TradingKey Stock Score of Trinity Biotech PLC

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Trinity Biotech PLC's Score

Industry at a Glance

Industry Ranking
158 / 210
Overall Ranking
458 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Trinity Biotech PLC Highlights

StrengthsRisks
Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 61.55M.
Fairly Valued
The company’s latest PE is -0.19, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 969.66K shares, increasing 42.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 11.39K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.62.

Trinity Biotech PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Trinity Biotech PLC Info

Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
Ticker SymbolTRIB
CompanyTrinity Biotech PLC
CEOMr. John Gillard
Websitehttps://www.trinitybiotech.com/
KeyAI